Phenotypeca is honoured to appoint Patrick Florent as non-Executive Chairman of the Board
We are delighted to announce Patrick Florent’s appointment to strengthen Phenotypeca’s Board of Directors. Patrick has worked for many years as Head of Global Strategic Partnership at GSK Vaccines and as Managing Director of their Belgian operations.
Commenting on his appointment, Keith Williams, Managing Director of Phenotypeca said “I have known Patrick for several decades, and I have been highly impressed by his clear thinking, understanding of how to communicate effectively to very different stakeholders, and proven strategic awareness. His appointment adds significant skill and expertise to our Board”.
Phenotypeca uses baker’s yeast libraries rich in natural biodiversity (over 1 billion strains) to improve biopharmaceutical manufacturing processes. They aim to make vaccines and therapeutics more accessible to those who need them and significantly reduce their cost for lower and middle-income countries (LMIC’s). This is one of our strategic activities, and Patrick has vast experience and an excellent network in the vaccine space, having been a Board Member for CEPI (The Coalition for Epidemic Preparedness Innovations) and leading their Sustainable Manufacturing Group.